Back to Results
First PageMeta Content
Oncolytic virus / Cancer treatments / Immunotherapy / Cancer / Metastasis / Reolysin / Oncolytics Biotech / Medicine / Viruses / Experimental cancer treatments


PSIOXUS THERAPEUTICS RECEIVES £1.8 MILLION TRANSLATION AWARD FROM THE WELLCOME TRUST TO TAKE ONCOLYTIC VIRUS INTO CLINIC ColoAd1 will enter phase I/II development for metastatic colorectal cancer in 2012 LONDON –12 Se
Add to Reading List

Document Date: 2011-12-20 03:27:39

Open Document

File Size: 62,80 KB

Share Result on Facebook

City

LONDON / /

Company

PsiOxusTherapeutics Ltd. / THE WELLCOME TRUST / PsiOxus Therapeutics Ltd. / /

Country

United Kingdom / /

Currency

GBP / /

/

Event

FDA Phase / /

IndustryTerm

stage biotechnology / treatment for Cachexia / a wasting syndrome / oncolytic product / therapy for cancer / treatment of metastatic cancer / treatment for cancer / as cancer therapies / /

MedicalCondition

serious chronic diseases / ovarian cancer / primary hepatocellular cancer / cancer / wasting syndrome / tumour / metastatic colorectal cancer / metastatic disease / metastatic cancer / clinically unmet diseases / /

MedicalTreatment

cancer therapies / /

Person

John Beadle / Erik Clausen / Tony Stephenson / /

/

Position

CEO / Chief Executive Officer / /

Product

ColoAd1 / MT-102 / /

Technology

biotechnology / /

URL

www.wellcome.ac.uk / www.PsiOxus.com / /

SocialTag